.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) Dionysis Partsinevelos
Mon, Jun 9, 2025, 7:27 AM 2 min read
In This Article:
We recently published a list of Jim Cramer Nailed These 11 Stock Predictions. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other stocks that Jim Cramer discusses.
Back then, a humorous caller asked if they should “bulk up” on Viking Therapeutics, Inc. (NASDAQ:VKTX), referencing both weight loss drugs and football. Cramer responded with his trademark flair and a clear preference:
“I even like the Vikings more than I like Viking Therapeutics — and that’s saying something ‘cause they ain’t that good. I say you need to be in Eli Lilly. Step your game up, partner.”
A microbiologist in protective gear studying samples in a laboratory.
Cramer favored Eli Lilly over Viking, and with VKTX down -52.27%, he made the better call.
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company developing treatments for metabolic and endocrine disorders, including obesity and liver disease.
Cramer remains firm in his opinion. Here’s what he said on January 30 this year:
“Okay, people, people think that even if Lily’s stock can’t go up, why would we want Viking Therapeutics? And a lot of people were in it for a takeover. So far it doesn’t look like that’s materializing, so they’re giving up and they are selling it. I prefer Eli Lilly.”
Overall, VKTX ranks 6th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of VKTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Comments